The Structured Commercial Strategy Framework for Cleared Medtech

FDA clearance is a regulatory event, not a commercial one. Most device companies conflate the two. The gap between clearance and clinical adoption is where most medtech revenue strategies fail.

A 510(k) clearance letter tells the market that your device is substantially equivalent to a predicate. It says nothing about whether physicians will adopt it, whether hospital value analysis committees will approve it, whether payers will cover it, or whether your clinical champions have the infrastructure to advocate for it.

The failure rate in medtech commercialization is not caused by bad products. It is caused by the assumption that clearance is the hard part. In most cases, clearance is the beginning of the hard part.

Bain & Company estimates the cost of a failed commercial launch for a cleared medical device at $500,000 to $2,000,000 in direct spend before the company recognizes the strategy is not working. That figure does not include opportunity cost, investor dilution pressure, or the erosion of clinical relationships that occurs when a launch is poorly structured.

This framework identifies five structural components that a cleared medtech company must have in place before meaningful commercial traction is possible. These are not best practices. They are the minimum viable conditions for a commercial strategy to function.

Component 1: Clinical Adoption Readiness Assessment

Before a single sales hire is made or a conference is attended, the company needs a grounded answer to a specific question: why would a physician adopt this product, and what would it take to change their current workflow to accommodate it?

This is not a market research question. It is a workflow question. The answer requires direct engagement with the procedural environment. understanding how the procedure is currently performed, who makes the adoption decision, what the reimbursement pathway looks like, and whether the clinical evidence is sufficient for the intended setting.

A clinical adoption readiness assessment maps this terrain. It identifies the path of least resistance to first adoption, the barriers that will slow or stop adoption, and the evidence gaps that need to be closed before a broader commercial push is credible. It is the document that should exist before a commercial hire is made.

Component 2: Defined KOL Architecture

Key opinion leaders are not the same as clinical enthusiasts. An enthusiast will use the product. A KOL will advocate for it in publications, at conferences, in physician peer conversations, and in hospital committee discussions. These are different functions, and they require different engagement structures.

A defined KOL architecture identifies: who the target KOLs are and why (specialty, procedural volume, publication history, institutional affiliation), what the engagement structure looks like (speaker bureau, advisory board, clinical investigation site, proctorship), and what compliance requirements govern each engagement type.

This last point is where most boutique advisory fails. The Sunshine Act requires disclosure of physician payments above de minimis thresholds. OIG guidance on fair market value sets limits on what can be paid for physician services. A KOL program built without a compliance architecture is a liability, not an asset. The physician relationships are real; the exposure is also real.

Component 3: Payer and Access Strategy

Clinical adoption without reimbursement coverage is a product demonstration, not a commercial strategy. The payer question must be answered before the commercial strategy is designed, not after the first year of sales reveals it is a barrier.

Payer strategy for medtech involves at minimum: identifying the CPT or Category III code that covers the procedure, understanding the coverage policy landscape across commercial payers and Medicare Administrative Contractors, and mapping the prior authorization requirements that will govern physician ordering behavior.

For devices entering the VA system, the pathway is different. The VA MISSION Act community care provisions have expanded the volume of procedures performed through community providers under VA coverage. Understanding how to position a device within VA formulary and CCN clinical pathways is a separate competency from commercial payer strategy and is largely absent from the advisory landscape.

Component 4: Evidence Strategy Aligned to Commercial Timeline

The evidence required to get a device cleared is not the evidence required to get it adopted. Hospital value analysis committees, health technology assessment bodies, and institutional formulary committees evaluate a different set of evidence than the FDA. Real-world effectiveness data, health economic modeling, and comparative effectiveness research are the evidence types that drive institutional adoption decisions.

An evidence strategy aligned to the commercial timeline identifies what evidence is needed for which decision-makers, and sequences the generation of that evidence to coincide with the commercial push. A post-market clinical study that completes two years after the commercial launch is not an evidence strategy. It is a research project.

Component 5: Commercial Infrastructure Defined Before It Is Built

The first commercial hire a medtech company makes is often the most consequential. Most early-stage companies make this hire before they have defined what success looks like, what the rep's territory and target list should be, what the sales cycle looks like, or how physician conversations should be structured.

A commercial infrastructure plan defines the sales model (direct vs. distributor vs. hybrid), the territory structure, the call routing logic, the go-to-market sequence (which accounts first, and why), and the metrics that will be used to evaluate commercial performance in the first 12 months. This plan should exist before the first rep is hired. Building it after the hire wastes the first six months of commercial activity on trial and error that could have been avoided.

---

The Common Thread

Each of these five components shares a common characteristic: they require clinical judgment, not just commercial execution. The decisions that determine whether a commercial strategy works are made at the intersection of clinical workflow, regulatory reality, and market access. not in the CRM or the marketing deck.

That is the scope of what US Health Strategy Group does: not marketing, not advertising, not sales force optimization. The strategy layer that sits underneath the commercial infrastructure and determines whether the infrastructure has anything to build on.